# CJC No DAC + Ipamorelin dosage & reconstitution (10 mg vial)

CJC No DAC + Ipamorelin dosage: calculations for a 10 mg vial use the same amounts described in the literature. Adding 2 mL of bacteriostatic water produces 5 mg/mL, so each U-100 unit contains 50 mcg.

- **Vial contents:** 10 mg CJC No DAC + Ipamorelin
- **Final volume:** 2 mL
- **Concentration:** 5 mg/mL
- **One U-100 unit:** 50 mcg in 0.01 mL

## Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing

### Standard / Gradual Approach (2 mL = ~5 mg/mL)

| Week / phase | Daily dose | Each peptide | Units per injection (mL) |
|---|---|---|---|
| Weeks 1–2 | 100 mcg | 3 units (0.03 mL) | 2 units (0.02 mL) |
| Weeks 3–4 | 150 mcg | 4.5 units (0.045 mL) | 3 units (0.03 mL) |
| Weeks 5–6 | 200 mcg | 6 units (0.06 mL) | 4 units (0.04 mL) |
| Weeks 7–12 | 300 mcg | 7.5–9 units (0.075–0.09 mL) | 6 units (0.06 mL) |

Frequency: Once daily, subcutaneously, at a consistent time.

### Reconstitution Steps

1. Draw 2 mL of bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid shaking to prevent foaming.
3. Gently swirl or roll until fully dissolved (clear solution).
4. Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.

Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

## U-100 Conversion Table

| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 100 mcg | 100 injections |
| 5 | 0.05 mL | 250 mcg | 40 injections |
| 10 | 0.10 mL | 500 mcg | 20 injections |
| 20 | 0.20 mL | 1 mg (1000 mcg) | 10 injections |
| 30 | 0.30 mL | 1.5 mg (1500 mcg) | 6 injections |
| 50 | 0.50 mL | 2.5 mg (2500 mcg) | 4 injections |
| 100 | 1.00 mL | 5 mg (5000 mcg) | 2 injections |

## Supplies Needed

**CJC No DAC + Ipamorelin vials (10 mg each)**
- Standard / Gradual Approach, 12 weeks: Minimum 2 vials (18.9 mg required).
- Standard / Gradual Approach, 24 weeks: Minimum 5 vials (44.1 mg required).

**U-100 syringes (1 mL)**
- Standard / Gradual Approach, 12 weeks: 84 new syringes for 84 injections.
- Standard / Gradual Approach, 24 weeks: 168 new syringes for 168 injections.

**Bacteriostatic water**
- Standard / Gradual Approach, 12 weeks: 4 mL total (2 mL per vial) → 2 × 3 mL vials.
- Standard / Gradual Approach, 24 weeks: 10 mL total (2 mL per vial) → 4 × 3 mL vials.

**Alcohol swabs**
- Standard / Gradual Approach, 12 weeks: 168 minimum; one box of 100 does not cover the calculation.
- Standard / Gradual Approach, 24 weeks: 336 minimum; one box of 100 does not cover the calculation.

## Storage Instructions

- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.

## How This Works

This synergistic combination represents one of the most-studied strategies for physiological pulsatile growth hormone (GH) stimulation through two complementary mechanisms: CJC-1295 without DAC (Modified GRF 1-29): GHRH analog (Growth Hormone Releasing Hormone) Sequence: 29 amino acids (vs 44 native GHRH) Molecular Weight: 3367.9 Da Key Modifications: Substitution Ala² → D-Ala² (DPP-4 resistance) Gln⁸ → Gln⁸ (stability) Ala¹⁵ → Leu¹⁵ (increased power) C-terminal truncation (aa 30-44 deleted) Ipamorelin: Synthetic ghrelin-mimetic pentapeptide Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ MW: 711.86 Da Selective GHSR-1a (GH secretagogue receptor) agonist Minimal activation of cortisol/ACTH/prolactin receptors Complementary Synergistic Mechanisms: CJC-1295 no-DAC (GHRHR Pathway): Pituitary GHRH receptor binding (somatotroph cells) Adenylate cyclase activation → ↑ cAMP → ↑ PKA Release of pre-synthesized GH vesicles GH gene transcription: expression upregulation Pulse amplification: 200-300% magnitude vs baseline Ipamorelin (GHS-R1a Pathway): Ghrelin receptor agonism in pituitary/hypothalamus Synergy with GHRH: 3-5x GH release potentiation Somatostatin inhibition (GHIH): tonic release Pulse…

## Research FAQ

**Why CJC-1295 WITHOUT DAC vs WITH DAC?** R: Critical differences:
**What is the optimal CJC-1295 to Ipamorelin ratio?** R: Ratios successfully studied:
**What's the best timing for administration for maximum effectiveness?** R: Circadian Considerations:
**P: ¿Desensibilización de receptores en estudios prolongados?** A: The literature describes the following as relevant factors:
**How to measure effectiveness in preclinical studies?** Acute (2-4h post-dose): Serum GH (ELISA, multiple time points)
**P: Compatibility with other compounds research?** R: Synergistic combinations studied:

## References

1. Teichman SL, et al. (2006) “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295” – Journal of Clinical Endocrinology and Metabolism 91(3):799-805. [PubMed: 16352683]
2. Johansen PB, et al. (1999) “Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats” – Growth Hormone IGF Receptor 9(2):106-113. [PubMed: 10373343]
3. Raun K, et al. (1998) “Ipamorelin, the first selective growth hormone secretagogue” – European Journal of Endocrinology 139(5):552-561. [PubMed: 9849822]
4. Svensson J, et al. (2000) “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats” – J Endocrinol 165(3):569-577. [PubMed: 10828839]
5. Ionescu M, Frohman LA. (2006) “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295” – American Journal of Physiology-Endocrinology and Metabolism 291(6):E1326-E1330. [PubMed: 16849630]
6. Beck DE, et al. (2014) “Ipamorelin produces GH release without cortisol or prolactinergic effects” - Growth Hormone IGF Receptor 24(4):139-145. [PubMed: 24853156]
7. Granata R, et al. (2007) “Cardiovascular actions of the ghrelin gene-derived peptide” – Endocrinology 148(2):514-523. [PubMed: 17068142]

---
Source: https://protocolopeptidos.com/en/compuestos/cjc-no-dac-plus-ipamorelin-10-mg · Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.